Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces
Key considerations document for developing and manufacturing challenge agents published
First site study awarded offering new site services since facilities expansion
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes market
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
Proposal to purchase Poolbeg Pharma shares from distribution in specie shareholders
hVIVO presents on the outcomes from the world’s first COVID-19 characterisation study
COVID-19 Characterisation Study peer reviewed results published in industry leading periodical Nature Medicine
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a
Open Orphan distribution in specie shares and in particular some people had been concerned that they were unable to trade them.
Volunteer Recruitment and Laboratory Facilities Expansion
